Suvi Heinimaki

Tampere, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.

Journal: Frontiers in immunology

Published: August 17, 2022

Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.

Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.

Journal: Virology

Published: November 04, 2021

Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses.

Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses.

Journal: Vaccines

Published: May 25, 2021

Modular vaccine platform based on the norovirus-like particle.

Modular vaccine platform based on the norovirus-like particle.

Journal: Journal of nanobiotechnology

Published: August 27, 2020

Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only.

Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only.

Journal: Vaccines

Published: June 17, 2020

Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform.

Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform.

Journal: Archives of virology

Published: June 13, 2020

Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure.

Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure.

Journal: Molecular immunology

Published: January 31, 2020

Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.

Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.

Journal: Antiviral research

Published: June 20, 2019

Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.

Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.

Journal: Journal of immunology research

Published: June 18, 2019

Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.

Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.

Journal: Vaccine

Published: May 02, 2019

A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine.

A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine.

Journal: Vaccine

Published: March 22, 2019

Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4+ T lymphocytes with cytotoxic potential.

Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4+ T lymphocytes with cytotoxic potential.

Journal: Antiviral research

Published: March 22, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026